<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561950</url>
  </required_header>
  <id_info>
    <org_study_id>F7HAEM-1955</org_study_id>
    <nct_id>NCT01561950</nct_id>
  </id_info>
  <brief_title>Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding</brief_title>
  <official_title>Use of Recombinant FVIIa to Mitigate Clopidogrel Anti-platelet Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of the America (USA). The aim of this trial is
      to evaluate the effectiveness of activated recombinant human factor VII to mitigate
      experimentally-induced bleeding in healthy volunteers treated with clopidogrel (PlavixÂ®).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding duration measured in minutes</measure>
    <time_frame>From onset of bleeding till the end of the bleeding</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood volume reported in millilitres</measure>
    <time_frame>From onset of bleeding till the end of the bleeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot dynamics on the TEG (thromboelastograph hemostasis analyzer): R in minutes</measure>
    <time_frame>Time to onset of clot formation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot dynamics on the TEG (thromboelastograph hemostasis analyzer): K in minutes</measure>
    <time_frame>Time to achieve 20 mm clot strength</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, including thrombotic events</measure>
    <time_frame>From screening to day 11-18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation-related parameters after pre-biopsy</measure>
    <time_frame>From baseline to 15 minutes after pre-biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation-related parameters after biopsy B2</measure>
    <time_frame>From baseline to 3 hours after B2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in coagulation-related parameters after biopsy B3</measure>
    <time_frame>From baseline to 1 hour after B3</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Haemostasis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Factor VII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eptacog alfa (activated)</intervention_name>
    <description>If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies</description>
    <arm_group_label>Factor VII</arm_group_label>
    <other_name>activated recombinant human factor VII</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).</description>
    <arm_group_label>Factor VII</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PT/PTT within normal laboratory range (e.g., PT: 9.4-12.0)

          -  Platelet count within normal laboratory range

        Exclusion Criteria:

          -  The receipt of any investigational drug within 1 month prior to this trial

          -  Use of anticoagulation therapy-defined as vitamin K antagonists, platelet antagonists,
             heparin

          -  (or low molecular weight heparin), aspirin or NSAIDs (non-steroidal anti-inflammatory
             drug) within 30 days prior to trial

          -  African-American race

          -  Weight above or equal to 160 kg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

